First Header Logo Second Header Logo

The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans.

Feldman SR, Wu JJ, Rastogi S, Menges B, Lingohr-Smith M, Lin J. The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans. J Med Econ. 2018 May; 21(5):537-541.

View in: PubMed